Octapharma Acquires Biovitrum's Plasma Products Division STOCKHOLM, Sweden, July 1, 2002 (PRIMEZONE) -- Biovitrum and Octapharma today announced that an agreement has been signed under which Octapharma will acquire Biovitrum's Plasma Products...

Biovitrum AB Initiates Phase I Clinical Trials for Novel Class Type II Diabetes Compound STOCKHOLM, Sweden, March 11, 2002 (PRIMEZONE) -- Biovitrum (LSE:BIO) today announced that it has entered Phase I studies with BVT.3498, a selective 11B HSD-1 inhibitor for the treatment of Type II...

Biovitrum Completes Successful Phase IIa Trial for Anti-Obesity Treatment (with link) STOCKHOLM, Sweden, Feb. 27, 2002 (PRIMEZONE) -- Biovitrum today announced the positive results of a phase IIa trial for its anti-obesity treatment BVT.933. "We are delighted to have achieved Proof...